Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Investors shouldn't count out Pfizer in the GLP-1 market just yet.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.